Allergan's ubrogepant meets in Phase III for acute migraine

Allergan plc (NYSE:AGN) said ubrogepant (MK-1602) met the co-primary endpoints in the Phase III ACHIEVE I trial for the acute treatment of migraine. The company expects data this half from the Phase III ACHIEVE II trial of ubrogepant in the indication, with an NDA submission to FDA planned for 2019.

ACHIEVE I enrolled patients ages 18-75 with a history of migraine who were treated for a single migraine attack of moderate or severe headache intensity with 50 or 100 mg oral ubrogepant or placebo...